Published in Gene Therapy Weekly, March 27th, 1995
Jean-Serge Remy et al. remark that most current ongoing human gene therapy protocols rely on recombinant retroviral and adenoviral vehicles which have limited carrier capacity and the possibility of safety and immunological problems with large scale or repeated use. Artificial viruses, although currently less efficient than biological vectors, show increasing promise of being the safer solution ("Targeted Gene Transfer into Hepatoma Cells with Lipopolyamine-Condensed DNA Particles Presenting Galactose Ligands: A Stage...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.